COLUMBIA LABORATORIES INC - FORM 10-Q - XML - IDEA: XBRL DOCUMENT - May 4, 2012

Attached files
FileFilename
EX-31.2 - EXHIBIT 31.2 - COLUMBIA LABORATORIES INCa2012q1ex-312.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR20.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR10.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR5.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR16.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR14.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR13.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR15.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR19.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR11.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR12.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR4.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR1.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR17.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR3.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR7.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR6.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR2.htm
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR8.htm
EXCEL - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - COLUMBIA LABORATORIES INCR9.htm
EX-32.2 - EXHIBIT 32.2 - COLUMBIA LABORATORIES INCa2012q1ex322.htm
EX-32.1 - EXHIBIT 32.1 - COLUMBIA LABORATORIES INCa2012q1ex321.htm
EX-31.1 - EXHIBIT 31.1 - COLUMBIA LABORATORIES INCa2012q1ex-311.htm
10-Q - CBRX FORM 10-Q - COLUMBIA LABORATORIES INCa2012q110q.htm
v2.4.0.6
Fair Value of Financial Instruments
 3 Months Ended
Mar. 31, 2012
FAIR VALUE OF FINANCIAL INSTRUMENTS [Abstract]  
Fair Value Disclosures [Text Block]
FAIR VALUE OF FINANCIAL INSTRUMENTS:
 Effective January 1, 2008, the Company adopted FASB ASC 820-10-25, (“Fair Value Measurement and Disclosures." This standard establishes a framework for measuring fair value and expands disclosure about fair value measurements. The Company did not elect fair value accounting for any assets and liabilities allowed by FASB ASC 825, “Financial Instruments.”
FASB ASC 820-10 defines fair value as the amount that would be received for an asset or paid to transfer a liability (i.e., an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. FASB ASC 820-10 also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. FASB ASC 820-10 describes the following three levels of inputs that may be used:
Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data.
Level 3: Unobservable inputs when there is little or no market data available, thereby requiring an entity to develop its own assumptions. The fair value hierarchy gives the lowest priority to Level 3 inputs.
The fair value of the short term investments are determined based on quoted market prices on the balance sheet date and are classified as a level 1 investment.
The estimated fair value of the Common Stock warrant liability resulting from the October 2009 registered direct offering of 10,900,000 shares of Common Stock and warrants to purchase 5,450,000 shares of Common Stock is shown in the table below and is determined by using the Black-Scholes option pricing model based on the Company's stock price at the measurement date, exercise price of the warrant, risk-free rate and historical volatility, and are classified as a Level 2 measurement. During the quarter ended March 31, 2012, the Company recorded income as shown in the table below to adjust the value of the stock warrant liability to market as a result of the change in the stock price from December 31, 2011.
 
March 31, 2012
 
December 31, 2011
 
Income (Expense) to adjust to market value
 
 
 
 
 
 
Common Stock Warrant Liability
$
1,909,479

 
$
8,168,846

 
$
6,259,367

 
 
 
 
 
 
 
March 31, 2011
 
December 31, 2010
 
Income (Expense) to adjust to market value
 
 
 
 
 
 
Common Stock Warrant Liability
$
14,345,017

 
$
9,286,906

 
$
(5,058,111
)
The estimated fair value of the Company's contingent obligation to purchase the Warrants issued under the Note Purchase Agreements, if the Company issued shares of Common Stock (or equivalents) for a price less than $2.00 per share until 45 days (January 20, 2011) after the Company's public announcement of the results of the PREGNANT Study, was determined under the Black-Scholes model and recorded as a liability at the closing of the Watson Transactions in the amount of $5,509,893 as of the close of business on July 1, 2010.  It was adjusted, as of December 31, 2010, to $13,471,832. The results of the PREGNANT Study were announced in December 2010, and on January 20, 2011, when the contingent purchase rights on the Warrants expired, As shown in the table below, the Company recorded expense to adjust the value of the redeemable warrants to market on January 20, 2011 determined under the Black-Scholes option pricing model as a result of the change in the stock price from December 31, 2011 and reclassified to Capital in Excess of Par Value. These Warrants will no longer be marked to market.
 
Time
 
Value
 
Income (Expense) to adjust to market value
Redeemable warrants
December 31, 2010
 
13,471,832

 
 
Value on January 20, 2011 when the contingent purchase rights on the Warrants expired
January 20, 2011
 
16,193,037

 
(2,721,205
)
Reclassified to Capital in Excess of Par Value
January 20, 2011
 
(16,193,037
)
 
 
Redeemable warrants
March 31, 2011
 
—

 
—

The fair value of accounts receivable and accounts payable approximate their carrying amount.

User Contributions:

Comment about this document or add new information about this topic:

CAPTCHA


This web site and associated pages are not associated with, endorsed by, or sponsored by COLUMBIA LABORATORIES INC and has no official or unofficial affiliation with COLUMBIA LABORATORIES INC


Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site.  Use at your own risk. This website is not associated with the SEC

Some parts © 2013 Advameg, Inc.